Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus

Paul Y. Kwo, Romil Saxena, Oscar Cummings, A. Joseph Tector

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Cholestatic hepatitis C virus (HCV) infection post orthotopic liver transplantation is associated with a poor prognosis. We describe 2 patients who received interferon and ribavirin for cholestatic HCV infection with clearance of HCV RNA from the serum. Both developed signs of graft failure necessitating repeat orthotopic liver transplantation, and at surgery, interferon was administered during the anhepatic phase to prevent graft reinfection. Both patients are doing well with no evidence of recurrent viremia at 36 and 24 months of follow-up after repeat transplantation, respectively. Our results suggest that in those with cholestatic HCV infection, repeat transplantation after viral clearance is feasible and can occur without reinfection of the graft, challenging the current practice of denying retransplantation for patients with cholestatic HCV. The role of anhepatic administration of interferon deserves further examination, and this combination may provide a solution in a subset of patients with an otherwise poor prognosis.

Original languageEnglish
Pages (from-to)1710-1713
Number of pages4
JournalLiver Transplantation
Volume13
Issue number12
DOIs
StatePublished - Dec 2007

Fingerprint

Hepacivirus
Interferons
Recurrence
Virus Diseases
Liver
Transplants
Liver Transplantation
Transplantation
Ribavirin
Viremia
RNA
Serum

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus. / Kwo, Paul Y.; Saxena, Romil; Cummings, Oscar; Tector, A. Joseph.

In: Liver Transplantation, Vol. 13, No. 12, 12.2007, p. 1710-1713.

Research output: Contribution to journalArticle

@article{b80b63c00b9e44798208552f3556f590,
title = "Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus",
abstract = "Cholestatic hepatitis C virus (HCV) infection post orthotopic liver transplantation is associated with a poor prognosis. We describe 2 patients who received interferon and ribavirin for cholestatic HCV infection with clearance of HCV RNA from the serum. Both developed signs of graft failure necessitating repeat orthotopic liver transplantation, and at surgery, interferon was administered during the anhepatic phase to prevent graft reinfection. Both patients are doing well with no evidence of recurrent viremia at 36 and 24 months of follow-up after repeat transplantation, respectively. Our results suggest that in those with cholestatic HCV infection, repeat transplantation after viral clearance is feasible and can occur without reinfection of the graft, challenging the current practice of denying retransplantation for patients with cholestatic HCV. The role of anhepatic administration of interferon deserves further examination, and this combination may provide a solution in a subset of patients with an otherwise poor prognosis.",
author = "Kwo, {Paul Y.} and Romil Saxena and Oscar Cummings and Tector, {A. Joseph}",
year = "2007",
month = "12",
doi = "10.1002/lt.21295",
language = "English",
volume = "13",
pages = "1710--1713",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus

AU - Kwo, Paul Y.

AU - Saxena, Romil

AU - Cummings, Oscar

AU - Tector, A. Joseph

PY - 2007/12

Y1 - 2007/12

N2 - Cholestatic hepatitis C virus (HCV) infection post orthotopic liver transplantation is associated with a poor prognosis. We describe 2 patients who received interferon and ribavirin for cholestatic HCV infection with clearance of HCV RNA from the serum. Both developed signs of graft failure necessitating repeat orthotopic liver transplantation, and at surgery, interferon was administered during the anhepatic phase to prevent graft reinfection. Both patients are doing well with no evidence of recurrent viremia at 36 and 24 months of follow-up after repeat transplantation, respectively. Our results suggest that in those with cholestatic HCV infection, repeat transplantation after viral clearance is feasible and can occur without reinfection of the graft, challenging the current practice of denying retransplantation for patients with cholestatic HCV. The role of anhepatic administration of interferon deserves further examination, and this combination may provide a solution in a subset of patients with an otherwise poor prognosis.

AB - Cholestatic hepatitis C virus (HCV) infection post orthotopic liver transplantation is associated with a poor prognosis. We describe 2 patients who received interferon and ribavirin for cholestatic HCV infection with clearance of HCV RNA from the serum. Both developed signs of graft failure necessitating repeat orthotopic liver transplantation, and at surgery, interferon was administered during the anhepatic phase to prevent graft reinfection. Both patients are doing well with no evidence of recurrent viremia at 36 and 24 months of follow-up after repeat transplantation, respectively. Our results suggest that in those with cholestatic HCV infection, repeat transplantation after viral clearance is feasible and can occur without reinfection of the graft, challenging the current practice of denying retransplantation for patients with cholestatic HCV. The role of anhepatic administration of interferon deserves further examination, and this combination may provide a solution in a subset of patients with an otherwise poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=34247246907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247246907&partnerID=8YFLogxK

U2 - 10.1002/lt.21295

DO - 10.1002/lt.21295

M3 - Article

C2 - 18044743

AN - SCOPUS:34247246907

VL - 13

SP - 1710

EP - 1713

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 12

ER -